ClinicalTrials.gg
RecruitingNCT07875556SCR-ADM-repairUpdated Oct 19, 2026

Arthroscopic Rotator Cuff Repair With Long Head of Biceps Transposition and Acellular Dermal Matrix Augmentation for Large to Massive Incompletely Repairable Rotator Cuff Tears

An interventional study of Rotator Cuff Repair and Long Head of the Biceps Tendon Transposition in Rotator Cuff Tears, Rotator Cuff Injuries and Massive Rotator Cuff Tear, sponsored by Tam Anh Research Institute. Recruiting at 1 site in Vietnam. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Tam Anh Research Institute · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 19, 2026Primary completion movedEligibility revised+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Study summary

Large-to-massive rotator cuff tears of the shoulder with poor tendon and muscle quality often cannot be fully repaired back to its footprint, and they have a high risk of re-tear. This study evaluates a combined technique for these tears.

During surgery, the torn rotator cuff is repaired as far as possible, the long head of the biceps tendon is transposed (rerouted) and fixed to the top of the humeral head, and the repair is augmented with an acellular dermal matrix graft (MegaDerm Plus, L\&C Bio, Republic of Korea). All participants receive the same operation and the same structured rehabilitation program; there is no comparison group.

Forty adults aged 40 to 75 years treated at Tam Anh General Hospital, Ho Chi Minh City, Vietnam, will be followed for 12 months after surgery. The main outcome is the rate of tendon retear on MRI at 12 months. Pain, shoulder function scores (Constant, ASES, UCLA), range of motion, muscle strength, X-ray findings and complications, including graft-related complications, will also be recorded.

Read the detailed description

Background and rationale:

Large-to-massive posterosuperior rotator cuff tears with severe fatty infiltration, muscle atrophy or tendon retraction often allow only incomplete repair, and retear rates after repair remain high. Two augmentation strategies have been described separately: partial superior capsule reconstruction using the rerouted long head of the biceps tendon (LHBT), and patch augmentation with an acellular dermal matrix (ADM). Direct clinical evidence for the combination of the two techniques is not yet available; the rationale of this study is based on indirect evidence from each component technique.

Design:

Prospective, single-center, single-arm case series (level of evidence IV) conducted at Tam Anh General Hospital, Ho Chi Minh City, as the clinical component of a doctoral dissertation at Hue University of Medicine and Pharmacy. A separate cadaveric biomechanical study within the same dissertation does not involve human participants and is not part of this registration.

Eligibility is assessed in two steps. Preoperative criteria are assessed clinically and on MRI. Intraoperative criteria (tear size, footprint coverage after maximal repair, and suitability of the LHBT for transposition) are confirmed arthroscopically. Participants who consented but do not meet the intraoperative criteria receive the most appropriate alternative procedure, are informed after surgery, and are not included in the analysis.

Intervention:

The surgery under general anesthesia combined with interscalene block, in the lateral decubitus position, and is performed by a single surgeon (H.V.D.A). After release of adhesions and footprint preparation, the LHBT is released from the bicipital groove and fixed to the superior greater tuberosity with a suture anchor. The rotator cuff is repaired with medial-row anchors (margin convergence and footprint medialization up to 10 mm when needed). An ADM graft (MegaDerm Plus, L\&C Bio; 2 mm thick; sized intraoperatively) is passed over the repair on the medial-row sutures and fixed laterally with a suture-bridge configuration using knotless lateral-row anchors.

MegaDerm Plus is registered in Vietnam as a Class D medical device (registration certificate No. 2501939ĐKLH/BYT-HTTB, issued 06 June 2025) and is used within its registered clinical use.

All participants follow the same phased postoperative rehabilitation protocol with defined criteria for progression between phases.

Follow-up and assessments:

Clinical assessments (VAS pain, Constant-Murley, ASES and UCLA scores, range of motion and shoulder strength) are performed preoperatively and at 3, 6 and 12 months after surgery. Radiographs are taken pre-operatovely and at 3 months to measure the acromiohumeral distance. MRI is performed preoperatively and at 3 and 12 months postoperatively. Tendon integrity is graded with the Sugaya classification; Sugaya type IV or V is defined as retear. MRI measurements are read independently by two radiologists, and inter-observer agreement is reported (kappa/ICC). Adverse events, including graft-related adverse events, are monitored throughout the 12-month follow-up.

Sample size and statistical analysis:

The study is descriptive and is not powered for a comparison with historical controls. The sample size was chosen to estimate the retear rate with acceptable precision: with 33 evaluable participants and no observed retear, the upper limit of the 95% confidence interval (rule of three) would be about 9%. Allowing approximately 10-15% loss to follow-up, 40 participants will be enrolled. The retear rate is reported as a proportion with its 95% confidence interval. Pre- and postoperative clinical scores are compared with paired t-tests or Wilcoxon signed-rank tests. Factors associated with retear and functional improvement (age, sex, tear size, Goutallier grade, RoHI score) are explored with linear or logistic regression. Analyses are performed in IBM SPSS with p \< 0.05 considered significant.

Ethics:

The protocol was approved by the Ethics Committee in Biomedical Research of Tam Anh General Hospital, Ho Chi Minh City (study code HV.26.09) and by the Ethics Committee of Hue University of Medicine and Pharmacy. Written informed consent is obtained from all participants. The study follows the Declaration of Helsinki and Good Clinical Practice.

02

Conditions studied

  • Rotator Cuff Tears
  • Rotator Cuff Injuries
  • Massive Rotator Cuff Tear

Browse trials for

Keywords

  • rotator cuff repair
  • partially repairable rotator cuff tear
  • long head of the biceps tendon transposition; biceps rerouting
  • acellular dermal matrix
  • graft augmentation
  • patch augmentation
  • retear
  • Sugaya classification
  • shoulder arthroscopy
03

In context

Rotator Cuff Injuries

745 studies on the registry are indexed under Rotator Cuff Injuries; 163 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 547 interventional studies indexed under Rotator Cuff Injuries.

Browse Rotator Cuff Injuries studies →

Lead sponsor

Tam Anh Research Institute is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preoperative:

    • Age 40 to 75 years
    • Large-to-massive posterosuperior rotator cuff tear (supraspinatus and/or infraspinatus) confirmed clinically and on MRI
    • Tear size greater than 3 cm on preoperative MRI
    • At least one risk factor for retear: severe muscle atrophy (occupation ratio \< 40%) or positive tangent sign; supraspinatus fatty infiltration Goutallier grade III or higher, or infraspinatus Goutallier grade II-III; or Rotator Cuff Healing Index (RoHI) \< 7
    • Tendon retraction Patte stage II or higher on MRI
    • No MRI evidence of complete rupture of the long head of the biceps tendon
    • Written informed consent
  • Intraoperative (all required for inclusion in the analysis):

    • Arthroscopically confirmed full-thickness tear of the supraspinatus and/or infraspinatus
    • Tear size greater than 3 cm in both anteroposterior and mediolateral dimensions, measured with a 5-mm graduated probe
    • Incomplete footprint coverage after maximal repair (less than 50% of the footprint) or Yoo type II-III
    • Long head of the biceps tendon Lafosse grade 0-II, suitable for transposition

Exclusion criteria

Exclusion Criteria:

  • Preoperative:

    • Glenohumeral arthritis / cuff tear arthropathy Hamada grade IV or higher
    • Subscapularis tear Lafosse type V (complete tear with humeral head decentering and Goutallier grade 3-4)
    • Previous surgery of the affected shoulder or shoulder deformity
    • Axillary nerve palsy or cervical nerve root injury
    • Shoulder joint infection
    • Neuromuscular conditions affecting postoperative rehabilitation (Parkinson disease, stroke with motor sequelae, severe dementia)
    • Refusal to participate or inability to comply with follow-up
  • Intraoperative:

    • Posterosuperior tear that cannot be repaired to the footprint to any degree after maximal release (irreparable)
    • Subscapularis tear of any Lafosse type that cannot be repaired to the footprint after maximal release
    • Long head of the biceps tendon Lafosse grade III, completely ruptured, or not suitable for transposition

Participants who consented but meet an intraoperative exclusion criterion receive the most appropriate alternative procedure, are informed after surgery, and are not included in the analysis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Rotator Cuff Repair + LHBT transposition + ADM Augmentation

    Arthroscopic incomplete repair of large-to-massive posterosuperior rotator cuff tears combined with long head of the biceps tendon transposition and acellular dermal matrix augmentation, followed by a standardized phased rehabilitation program.

    Procedure: Rotator Cuff Repair · Procedure: Long Head of the Biceps Tendon Transposition · Device: Acellular Dermal Matrix (Allograft) Augmentation

Interventions

  • ProcedureRotator Cuff Repair

    Arthroscopic repair of the posterosuperior rotator cuff to the maximum achievable footprint coverage after release of adhesions, using double-loaded medial-row suture anchors, with margin convergence and footprint medialization (up to 10 mm) when needed.

  • ProcedureLong Head of the Biceps Tendon Transposition

    The long head of the biceps tendon is released from the bicipital groove, transposed to the superior greater tuberosity and fixed with a double-loaded suture anchor placed 5 mm lateral to the articular margin, using two lasso-loop stitches.

    Also known as: Biceps rerouting; LHBT transposition, Biceps superior capsule reconstruction; LHBT superior capsule reconstruction; LHBT SCR

  • DeviceAcellular Dermal Matrix (Allograft) Augmentation

    A 2-mm-thick acellular dermal matrix graft, sized intraoperatively, is passed over the repair on the medial-row sutures and fixed laterally in a suture-bridge configuration with knotless lateral-row anchors. The device is registered in Vietnam as a Class D medical device (No. 2501939ĐKLH/BYT-HTTB).

    Also known as: MegaDerm Plus (L&C Bio, Republic of Korea)

06

What researchers measure

Primary outcomes

  1. Rotator Cuff Retear Rate on MRI

    Proportion of participants with retear, defined as Sugaya type IV or V on postoperative MRI (T2-weighted), read independently by two radiologists blinded to clinical outcome scores; disagreements resolved by consensus or third-reader adjudication. Reported as a percentage with 95% confidence interval.

    Time frame: 12 months after surgery

Secondary outcomes

  1. Tendon Integrity (Sugaya Classification) on MRI

    Distribution of Sugaya types I-V (I = best integrity, V = major discontinuity) on postoperative MRI, read independently by two radiologists.

    Time frame: 3 months and 12 months after surgery

  2. Pain Intensity (Visual Analog Scale)

    VAS pain score from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: Preoperative (baseline), 3, 6 and 12 months after surgery

  3. Constant-Murley Score

    Shoulder function score from 0 to 100; higher scores indicate better function.

    Time frame: Preoperative (baseline), 3, 6 and 12 months after surgery

  4. American Shoulder and Elbow Surgeons (ASES) Score

    Score from 0 to 100 combining pain and activities of daily living; higher scores indicate better function.

    Time frame: Preoperative (baseline), 3, 6 and 12 months after surgery

  5. UCLA Shoulder Score

    Score from 0 to 35; higher scores indicate better shoulder function.

    Time frame: Preoperative (baseline), 3, 6 and 12 months after surgery

  6. Shoulder Range of Motion

    Active and passive forward elevation, external rotation and external rotation at 90° abduction (degrees, goniometer); internal rotation recorded as the highest vertebral level reached by the thumb.

    Time frame: Preoperative (baseline), 3, 6 and 12 months after surgery

  7. Shoulder Abduction Strength

    Manual muscle testing (MRC grade 0-5) and hand-held dynamometer (Newtons), measured with the shoulder abducted, thumb up and elbow extended

    Time frame: Preoperative (baseline), 3, 6 and 12 months after surgery

  8. Acromiohumeral Distance on Radiograph

    Shortest distance (mm) between the undersurface of the acromion and the superior humeral head on an anteroposterior shoulder radiograph

    Time frame: Pre-operative and at 3 months after surgery

  9. Adverse Events, Including Graft-Related Adverse Events

    Number of participants with adverse events, including wound complications, infection, nerve or vessel injury, sterile inflammatory reaction, graft rejection or foreign-body reaction, and reoperation; relationship to the device is assessed for each event

    Time frame: From surgery to 12 months after surgery

  10. Integrity of the Transposed Long Head of the Biceps Tendon on MRI

    Continuity of the transposed LHBT between the supraglenoid origin and the anchor fixation on the greater tuberosity on postoperative MRI, classified as intact or discontinuous (rupture or detachment), read independently by two radiologists.

    Time frame: 3 months and 12 months after surgery

07

Study locations

1 of 1 sites recruiting
  • Tam Anh TP. Ho Chi Minh General Hospital
    Ho Chi Minh City, Ho Chi Minh 700000, Vietnam
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. The informed consent restricts data access to the research team, the Ethics Committee and regulatory authorities, and states that results will be published only in aggregate form.

No publications or documents are linked to this record.

09

Updates

2 registry updates since Sep 25, 2026
Primary completion
Sep 16, 2029→Sep 30, 2030
Oct 19, 2026
Also revised
eligibility, primary outcomes and interventions
Registered
First appeared on the registry
Oct 15, 2026
Show all 2 updates
  1. Oct 19, 2026
    Primary completion Sep 16, 2029→Sep 30, 2030
    Eligibility Criteria revised
    Primary outcomes Revised (1 change)
    Interventions Arms or interventions changed
    + 7 other changes: index terms, identifiers, description, design details, secondary outcomes, contact details and data sharing statement
  2. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07875556
Lead sponsor
Tam Anh Research Institute
Collaborators
Hue University of Medicine and Pharmacy
Responsible party
Hồ Văn Duy Ân (Orthopedic Surgeon, Center of Trauma and Orthopedics, Tam Anh General Hospital, Ho Chi Minh City, Tam Anh Research Institute) — Principal investigator
First posted
Oct 15, 2026
Start date
Sep 16, 2026
Primary completion
Sep 30, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Duy Ân Văn Hồ, M.D., M.Sc.
Contact
anhvd@tahospital.vn
+84839412663

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion